Why Ohr Pharmaceuticals (OHRP) Stock Is Soaring Today

NEW YORK (TheStreet) -- Ohr Pharmaceuticals  (OHRP) soared Thursday after Vista Partners increased its price target on the stock to $31 from $14.

The stock plunged Tuesday after it reported results of its phase II study on its Squalamine eye drop. For more on that, read TheStreet's Adam Feuerstein's article here.

Ohr closed up 35.43%, or $2.59, to $9.90 on Thursday. More than 5.7 million shares changed hands, compared to the average volume of 401,319.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

OHRP Price Chart

OHRP Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

Ohr Pharma (OHRP) Stock Surges After Launching Phase 3 Trial

8 Stocks Under $10 Making Big Moves Higher

5 Stocks Under $10 Set to Soar

3 Stocks Under $10 Making Big Moves